Skip to main content
letter
. 2015 Apr;100(4):e158–e161. doi: 10.3324/haematol.2014.116111

Figure 4.

Figure 4.

Evaluation of B-cell responses to de novo rubella and tetanus toxoid vaccination. (A and B) IgG titers were determined with Enzygnost® ELISA. (C and D) Antigen-specific MBCs and (E) BMPCs were quantified with ELISPOT. Proportions of (C) rubella-specific and (D) tetanus-specific MBCs. Specific IgG titers were significantly lower in the treated group on day 101 against both rubella (A) (P=0.025) and tetanus (B) (P=0.032). On day 101, the number of specific MBCs was significantly lower in the treated group for rubella (C) (P=0.002) and tetanus (D) (P=0.05). The mean rubella-specific MBC ratio increase from day 101 to 211 was lower in the treated group, but this difference was not statistically significant (P=0.083). (E) Rubella-specific BMPC proportions with no significant differences between the groups.